Bioorganic and Medicinal Chemistry Letters p. 2957 - 2960 (2018)
Update date:2022-08-03
Topics:
Huang, Yaping
Sun, Geng
Wang, Pengfei
Shi, Rui
Zhang, Yanchun
Wen, Xiaoan
Sun, Hongbin
Chen, Caiping
In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I.
View MoreJiangsu Hualun Chemical Industry Co., Ltd
website:http://www.hualunchem.com
Contact:+86-0514-86464168 86507985
Address:39# Middle Renmin Road, Dinghuo Town
Guilin Zhenda Bio-Tech Co., Ltd.
Contact:86-773-3568977
Address:-Yangtang shangshui industry park, Lingui county,
Chengdu Aslee Biopharmaceuticals, Inc
Contact:18608018419
Address:Chengdu Aslee Biopharmaceuticals, Inc
Chengdu Green technology Co.,Ltd.
Contact:86-28-82608355
Address:C9 ,Economic Headquarters, Economic Development Zone, Chengdu.
HENAN NEW BLUE CHEMICAL CO.,LTD
website:http://www.newbluechem.com
Contact:86-371-55170693/55170694
Address:Zhengzhou International Trade New Territory,Jinshui District,Zhengzhou ,China
Doi:10.1016/j.tet.2013.05.064
(2013)Doi:10.1007/s10593-005-0179-3
(2005)Doi:10.1016/S0040-4039(01)91051-2
(1984)Doi:10.1016/j.tet.2006.12.088
(2007)Doi:10.1016/j.tetlet.2006.12.109
(2007)Doi:10.1016/j.apcata.2014.08.009
(2014)